Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values

RESULTS FROM THE FENOFIBRIC ACID ON CAROTID INTIMA-MEDIA THICKNESS IN SUBJECTS WITH TYPE IIB DYSLIPIDEMIA WITH RESIDUAL RISK IN ADDITION TO ATORVASTATIN THERAPY (FIRST) TRIAL

(2013) Michael H. Davidson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study

(2012) Christie M. Ballantyne et al.   AMERICAN HEART JOURNAL

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

(2012) Harold E. Bays et al.   Journal of Clinical Lipidology

Pitavastatin 4 Mg Significantly Reduces LDL-P and Increases HDL Size Compared with Pravastatin 40 mg: Results from PREVAIL US

(2012) Craig A. Sponseller et al.   Journal of Clinical Lipidology

Changes in Lipoprotein Particle Number with Ezetimibe/Simvastatin Co-administered with Extended-Release Niacin in Patients with Type II Hyperlipidemia†

(2012) Ngoc-Anh Le et al.   Journal of Clinical Lipidology

Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus

(2012) Ronald B. Goldberg et al.   Journal of Clinical Lipidology

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib

(2012) Michael Davidson et al.   JOURNAL OF LIPID RESEARCH

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

(2012) Michael J Koren et al.   LANCET

Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus

(2012) Harold Bays et al.   Metabolic Syndrome and Related Disorders

Effects of Atorvastatin on Nuclear Magnetic Resonance-Defined Lipoprotein Subclasses and Inflammatory Markers in Patients with Hypercholesterolemia

(2011) Katsunori Ikewaki et al.   Journal of Atherosclerosis and Thrombosis

Effects of Prescription Omega-3-Acid Ethyl Esters on Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia

(2011) Kevin C Maki et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

(2011) Michael H. Davidson et al.   Journal of Clinical Lipidology

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number

(2011) James D. Otvos et al.   Journal of Clinical Lipidology

Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk

(2010) Robert S. Rosenson et al.   ATHEROSCLEROSIS

Initial Combination Therapy With Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals in Early Type 2 Diabetes

(2010) Julio Rosenstock et al.   Endocrine Practice

Lipid assessment, metabolic syndrome and coronary heart disease risk

(2010) Benoit J. Arsenault et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women

(2009) Samia Mora et al.   CIRCULATION

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

(2009) J. H. Contois et al.   CLINICAL CHEMISTRY

Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled study

(2009) R. S. Rosenson et al.   DIABETES CARE

Colestimide, an anion exchange resin agent, can decrease the number of LDL particles without affecting their size in patients with hyperlipidemia

(2009) Noriaki Kishimoto et al.   Journal of Cardiology

Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering—lipoprotein changes and interactions: the SANDS study

(2009) Wm. James Howard et al.   Journal of Clinical Lipidology

Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease

(2009) William C. Cromwell et al.   Current Cardiology Reports

Fenofibrate reduces lipoprotein associated phospholipase A 2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

(2008) Robert S. Rosenson   AMERICAN HEART JOURNAL

Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD

(2008) Haseeb Jafri et al.   Journal of Clinical Lipidology

Atherogenic Lipoprotein Particle Size and Concentrations and the Effect of Pravastatin in Children with Familial Hypercholesterolemia

(2008) Anouk van der Graaf et al.   JOURNAL OF PEDIATRICS

Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia

(2007) Makoto Ayaori et al.   ATHEROSCLEROSIS